
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
— Hippocrates

Focused ultrasound neuromodulation represents a revolutionary frontier for treating complex neurological disorders. This non-invasive technology uses acoustic energy to target deep brain structures precisely. However, most preclinical research relies on healthy animal models. Consequently, understanding how a diseased brain reacts differently than a healthy one is essential for clinical progress.
Recent research investigated how Parkinson’s disease (PD) impacts the efficacy of focused ultrasound neuromodulation. Scientists used a unilateral dopamine depletion model to compare responses between healthy and diseased mice. They specifically targeted the left external globus pallidus (GPe) using a wearable device. Interestingly, the results showed that the disease state completely changed the brain's response to the intervention.
In mice with Parkinson’s, the stimulation significantly inhibited GPe calcium activity for approximately three minutes. Furthermore, this physiological change led to dramatic motor improvements. The researchers observed a reduction in ipsilateral circling that persisted for at least 50 minutes after the session. In contrast, healthy mice showed no significant changes in calcium levels or rotational behavior.
One major concern with any deep-brain intervention is the potential for tissue damage. Fortunately, histological analysis confirmed that this specific protocol caused no neuronal damage or inflammation. There was no evidence of astrocytic activation or microglial proliferation in either group. These safety findings support the potential for translating this technology into human clinical trials.
Notably, the transient inhibition of the GPe appears to correct the pathological overactivity typical of the Parkinsonian state. This selective response highlights why evaluating neuromodulation strategies in relevant disease models is critical. Therefore, future therapies must account for the specific neurochemical environment of the patient’s brain to ensure maximum therapeutic benefit.
In this study, the inhibition of brain cell activity lasted for three minutes, while the improvements in motor movement lasted for 50 minutes after stimulation.
No. Histological exams revealed no signs of cell death, scarring, or immune system activation in the brain regions targeted by the ultrasound.
The ultrasound appears to correct specific imbalances caused by dopamine loss. Because healthy mice do not have these imbalances, the stimulation does not produce the same inhibitory or behavioral effects.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and is not intended to replace professional judgment or treatment. Refer to the latest local and national guidelines for clinical practice.
References

New research shows focused ultrasound neuromodulation selectively inhibits GPe activity and improves motor function in Parkinson's mice, but not in healthy ...
3 months ago

Study identifies core symptoms and clusters in 1156 hemodialysis patients, highlighting nervousness and worry as key drivers of overall symptom burden....
Today

Research highlights a new FHIR-based information model for prenatal monitoring, promoting seamless data exchange and higher quality maternal care in primary...
Today

A Swiss cohort study finds that recipient-donor sex mismatch doesn't impact infection risk, but female kidney recipients face higher infection rates....
Today

A study introduces high-stability wool-based artificial muscles stabilized by disulfide bonds, offering potential for smart bionic arms and surgical tools....
Today

A study of 5,129 pediatric colonoscopies found that 8% of patients develop hypoglycemia after bowel preparation, especially younger and underweight children...
Today